The point is the patient
A trial that enrolls a year late is a year of people living with Crohn's or colitis waiting on an answer.
About
Be the best software for one workflow.
We are building the fastest way for IBD research coordinators to understand trial eligibility and organize participant screening — so new Crohn's and ulcerative colitis treatments reach patients sooner. That is the whole product, and we would rather do it properly than do ten things adequately.
Statement of purpose
Inflammatory bowel disease trials are among the hardest studies to enroll. Eligibility turns on composite activity indices, centrally read endoscopy, and prior-therapy history written in clinical shorthand — and competing Crohn's and ulcerative colitis studies draw from the same narrow pool of patients, often at the same centers.
So we picked one workflow and went deep on it: the coordinator's work of reading eligibility, writing it out so the team agrees on it, and ordering the screening list. That is useful on day one — it needs the protocol and the lists a study team already keeps, not a record integration.
Long-term visionCoordinators face the same problem in most therapeutic areas: eligibility is written for adjudication rather than screening, and the organizing happens in spreadsheets. IBD is where we learn to do it properly. The intent is to become the operating layer for clinical trial recruitment across every therapeutic area — earned one indication at a time, not claimed up front.
The software does not access live hospital records and does not identify real patients. Research teams decide what enters the workspace, and every generated output is a draft awaiting human review.
One disease area, properly
We would rather be genuinely useful in IBD than superficially present in forty indications.
Say only what is true
We describe what the software does in plain terms and label every synthetic figure as synthetic.
Judgement stays with the team
The software structures information. The clinical and operational decisions remain with the investigator.
Correspondence